Oral vs Extended-Release Naltrexone for Opioid Use Disorder
The Carlat Addiction Treatment Report, Volume 7, Number 3&4, May 2019
https://www.thecarlatreport.com/newsletter-issue/catrv7n34/
Issue Links: Learning Objectives | Editorial Information
Topics: Addiction Treatment | Naltrexone | Opioid Use Disorder | Research Update
Jessica Goren, PharmD.
Dr. Goren has disclosed that she has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Extended-release (XR) naltrexone (Vivitrol) is FDA approved for opioid use disorder and has shown efficacy in several trials. It works best for patients who have already successfully detoxed from opioids and who are highly motivated to abstain. But what about oral naltrexone?
You can't view details of this content, please login or buy subscription here